Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Adjuvant gefitinib improves outcomes in non-small cell lung cancer (NSCLC) patients compared to chemotherapy, but not in all cases. Here, the authors find genomic biomarkers of response to gefitinib in NSCLC patients from the ADJUVANT trial, and propose a score to stratify them by potential benefit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Si-Yang Liu, Hua Bao, Qun Wang, Wei-Min Mao, Yedan Chen, Xiaoling Tong, Song-Tao Xu, Lin Wu, Yu-Cheng Wei, Yong-Yu Liu, Chun Chen, Ying Cheng, Rong Yin, Fan Yang, Sheng-Xiang Ren, Xiao-Fei Li, Jian Li, Cheng Huang, Zhi-Dong Liu, Shun Xu, Ke-Neng Chen, Shi-Dong Xu, Lun-Xu Liu, Ping Yu, Bu-Hai Wang, Hai-Tao Ma, Hong-Hong Yan, Song Dong, Xu-Chao Zhang, Jian Su, Jin-Ji Yang, Xue-Ning Yang, Qing Zhou, Xue Wu, Yang Shao, Wen-Zhao Zhong, Yi-Long Wu
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/c64a379b331b42709e78b568f7636af6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

Ejemplares similares